AnalystsAlex ArfaeiAlex Arfaei's Stock Forecasts
AnalystsAlex Arfaei
Analyst Ranking
Top 17%
#756 out of 4577 analysts
Average Return
+14.21%
Win Rate
96%24 out of 25
Risk vs Reward
Poor
Good
Alex Arfaei's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Merck & Co IncMRK | +37.41% | $54.90 | $75.44 | 2018-02-13 - 2019-01-23 | Buy |
Merck & Co IncMRK | +33.62% | $55.09 | $73.61 | 2017-10-30 - 2018-10-31 | Buy |
Bristol Myers Squibb CoBMY | +32.31% | $45.80 | $60.60 | 2019-04-16 - 2020-04-17 | Buy |
Abbvie IncABBV | +31.77% | $115.88 | $79.06 | 2018-01-29 - 2019-01-30 | Sell |
Merck & Co IncMRK | +26.98% | $59.41 | $75.44 | 2018-04-25 - 2019-01-23 | Buy |
Alex Arfaei Analyst Color
Get additional color on Alex Arfaei's coverage of popular stocks
Alex Arfaei's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Bristol Myers Squibb CoBMY | 12 | Buy | $63.00 | N/A | Maintains | 5 years ago |
Zoetis IncZTS | 3 | Hold | $101.00 | N/A | Maintains | 5 years ago |
Merck & Co IncMRK | 6 | Hold | $80.00 | N/A | Downgrades | 5 years ago |
Abbvie IncABBV | 5 | Sell | $71.00 | N/A | Maintains | 6 years ago |
Pfizer IncPFE | 5 | Hold | N/A | N/A | Downgrades | 6 years ago |
Eli Lilly & CoLLY | 10 | Buy | $130.00 | N/A | Upgrades | 6 years ago |
Astrazeneca PLCAZN | 1 | Buy | $38.00 | N/A | Initiates Coverage On | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.